RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ORAL ALBUTEROL IN INFANTS WITH MILD-TO-MODERATE ACUTE VIRAL BRONCHIOLITIS

• DOI: 10.1542/peds.114.s1.542b
• Publication Date: 2021-12-08T21:57:52Z
• Authors: Joseph Shapiro; Michael S. Kaplan
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

Patel H, Gouin S, Platt R. J Pediatr. 2003;142:509–514To determine whether oral albuterol therapy is effective in reducing symptoms of mild/moderate acute viral bronchiolitis.A total 129 previously healthy infants (≤12 months age) discharged directly home from the emergency department (ED), with a clinical diagnosis bronchiolitis, were studied.At discharge ED, patients randomly assigned to receive either (0.1 mg/kg per dose) or placebo treatment. Infants treated 3 times daily for maximum 7 days until complete resolution bronchiolitis symptoms, whichever happened first. Overall health, medication compliance, feeding and sleeping patterns, follow-up visits, parental life disruptions, adverse events discussed telephone interviews 14 days. The primary outcome interest was time study enrollment illness, as determined by caregiver. Secondary outcomes included duration cough, coryza, noisy breathing, normal feeding, sleeping.During study, 1039 hospital ED bronchiolitis. Of those, 231 eligible randomized into study. mean ages 5.4 group 5.1 group. Respiratory syncytial virus pathogen found most frequently (albuterol: 81%; placebo: 79%) nasopharyngeal aspirates collected 61 2 groups. median number illness before presentation both groups 4.0 similar 8.9 days; 8.4 days). There no significant differences secondary between Hospitalization treatment respiratory distress eventually required 4 5 numbers health care revisits 1; 0). also which trembling vomiting observed 0 1, respectively).There difference symptom newly diagnosed orally administered versus placebo. authors did not recommend use this patient population.Although previous studies results, based solely on subjective evaluations caregiver at home. present compelling evidence that albuterol, dose used has little role among infants. However, low end recommended range 0.1 0.2 mg/ kg dose, daily.